KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

About this update from Koru Medical Systems, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/69720d6aa82ea4b1888fb405d1d3e5fa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PU_kZMYeR3W5o1Uda8c09A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/69720d6aa82ea4b1888fb405d1d3e5fa","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/WJJTPltf4f4pgPkfKxoLzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/69720d6aa82ea4b1888fb405d1d3e5fa","width":1024,"height":512}},"lazy":false},{"type":"text","content":"MAHWAH, N.J., May 07, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025.","length":396,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period","length":91,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period","length":114,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over the prior year period","length":155,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Ending cash balance of $8.7 million and quarterly cash usage of $0.8 million","length":76,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announcing plans to submit for FDA 510(k) clearance for 2 commercialized drugs with the Freedom Infusion System™ in 2025","length":120,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Raising full year 2025 revenue guidance to $38.5 – $39.5 million from prior range of $38.0 - $39.0 million; reiterating f...

More updates from Koru Medical Systems, Inc.